Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. - Wikidata - wikimedia - TriplyDB

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

http://www.wikidata.org/entity/Q39916505

about

A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting Novel Methods of Enhanced Retention in and Rapid, Targeted Release from Liposomes.Combinatorial peptide libraries: mining for cell-binding peptides.Antivascular therapy for epithelial ovarian cancer.PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy.Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model.Aminopeptidase N (CD13) as a target for cancer chemotherapy.F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo.Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma Tumor-targeting peptides from combinatorial libraries.Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.Recent advances in drug delivery strategies for treatment of ovarian cancer.Tumor endothelial markers as a target in cancer.The effects of engineered nanoparticles on pulmonary immune homeostasis.Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma.Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.

P2860

Q27308658-01CBB36D-426C-4A89-B545-FC5C910A5AC2 Q30456053-F3799554-00C2-4108-A589-C262518969AA Q30466993-73CBAF9C-76F0-425E-A562-7AE9509F141C Q31144876-DE4B6AD0-147E-47F6-9F46-FAC0C7C66D85 Q33583598-7B2646A8-31FC-4AEF-AC1A-E95B5FBC5B83 Q33721880-AF9658E3-7372-4CE2-989B-CFB54F0603F3 Q33829569-557ECEA9-782C-4FF8-A9BC-E9A56779B173 Q33897492-CB8FD35F-031D-49A7-9EC3-601D4FDF5D47 Q33968452-E59B57B5-9378-4942-A42B-9B1584CE398C Q34051924-01EF25E0-890B-4CD0-9828-E60256EC2552 Q34157418-7F41222A-D6B1-4B5D-9F12-4E8402D2D55A Q34268119-A21B933A-0C89-4119-B596-E071493BDC91 Q35049970-1DC53158-01A0-4737-8F1E-A6066B717D36 Q35086721-EA0F16DF-3C01-4348-98E1-AFB0319A8FA8 Q35161323-470070AE-5D24-44CA-8C96-79F1574951E6 Q35623435-A1FDB57E-168A-4A25-83ED-788C233F5A0C Q36025723-C3D76897-1E05-4FD5-947B-8AFD1424A106 Q36184480-DEAE2E74-4701-458F-AD80-DD2EB43B949C Q36557133-C3215FB6-FF8E-49C2-A932-CC7581858603 Q37717652-25550932-3741-46C8-A7E9-B7B0AAD5E19B Q37997512-4C2CFF1B-BCEB-48C5-91D8-A4ABA02524ED Q38043525-2E9C376F-1007-46D0-8951-DE888C562023 Q38165210-6CA72954-D9E5-4F93-8559-63002063EAAB Q39113077-B352497A-5ECC-43BD-A0C7-566B0E706508 Q39324636-8D83DFD2-0B12-4F41-B8B6-3013D8276A79

P2860

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

http://www.wikidata.org/entity/Q39916505

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

@en

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

@nl

type

label

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

@en

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

@nl

prefLabel

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

@en

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

@nl

P1433

Q39916505-BEEC4BAD-AA8F-4565-AEBF-76A70C5A50D5

P1476

Q39916505-852F3419-178A-401B-A577-C9205CD99439

P2093

Q39916505-5500F1FA-78A9-47FE-B8B9-C12B28957965

Q39916505-746D51B6-3A42-4FF1-BD42-D4253C8AD68E

Q39916505-7BC678C7-6A1F-4FE4-BC71-CEE55ADA30C8

Q39916505-87355638-6199-4C3D-B4F9-F96203D1B1F5

Q39916505-8DD5D04E-4FD9-4E30-ADAB-6053C066354D

Q39916505-9BA5DE16-07E7-4766-9529-6410524B669E

Q39916505-9BDC5600-5AC2-40DB-93AA-F4E1339AF7C9

Q39916505-B757C49B-0179-467A-9FE5-4B402A53F2A2

Q39916505-BEE0C1BE-ECD5-4F22-A0C7-96D1FD7B6F3E

Q39916505-C2D5DFE4-E4D8-42F5-A28C-67B2B32F7865

P304

Q39916505-49F8F4B2-54CE-4857-BE20-643C1A16F8DF

P31

Q39916505-D7FB3D16-F255-47A4-ACA2-A46338A363DF

P356

Q39916505-9C21320C-5010-4CBE-9C13-8D088F80F57A

P407

Q39916505-503C7F51-8A95-46AC-90CF-4D9D185C6AF9

P433

Q39916505-9CB90D8D-FDFA-4BE6-BE84-3D20E239AB82

P478

Q39916505-96949EE2-56F3-4483-97E3-58C2F381016A

P50

Q39916505-11E9C3B7-0C54-4596-8FD8-8B87B2CD439A

Q39916505-27E2DA37-3132-4F90-89CA-423B744AD36E

Q39916505-569CFD73-6176-49D4-B9D3-20EEFEE94C57

Q39916505-5F645261-7478-4649-B464-50D6DEFBA8D6

Q39916505-AA8608AA-E407-4308-8FDA-79307AEEFB81

Q39916505-B11C1907-C991-4D40-9E1F-722F31529285

Q39916505-BDB7F547-45D5-4BAB-9DFD-C29AC787E10D

Q39916505-C23BE5D8-F05B-41E1-BFC9-1324B8149D72

P577

Q39916505-F0B1BEAD-6280-4C3A-A6C6-50BDAC81B6DE

P698

Q39916505-572C8F73-0F97-4604-AA54-69F20382BFAC

P356

1078-0432.CCR-08-0804

P1433

Clinical Cancer Research

P1476

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

@en

P2093

Beatrice Nico

http://www.w3.org/2001/XMLSchema#string

Carlo E Neumaier

http://www.w3.org/2001/XMLSchema#string

Chiara Brignole

http://www.w3.org/2001/XMLSchema#string

Danilo Marimpietri

http://www.w3.org/2001/XMLSchema#string

Eugene A Lepekhin

http://www.w3.org/2001/XMLSchema#string

Federica Piccardi

http://www.w3.org/2001/XMLSchema#string

Jinzi J Wu

http://www.w3.org/2001/XMLSchema#string

Michele Cilli

http://www.w3.org/2001/XMLSchema#string

Monica Loi

http://www.w3.org/2001/XMLSchema#string

Renato Longhi

http://www.w3.org/2001/XMLSchema#string

P304

7320-7329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0804

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Daniela Di Paolo

Fabio Pastorino

Gabriella Pagnan

Domenico Ribatti

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19010847

http://www.w3.org/2001/XMLSchema#string